NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abiomed, Inc. (“Abiomed” or the “Company”) (NASDAQ: ABMD). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980.
The investigation concerns whether Abiomed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On August 1, 2019, Abiomed announced its financial results for the first quarter of 2019. Among other results, Abiomed announced its third consecutive quarter of slowing revenue growth, and the Company’s full-year guidance expectations fell roughly $22 million short of market expectations. On this news, Abiomed’s stock price fell sharply on August 1, 2019.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby